Novartis has received approval from the Food and Drug Administration for the treatment of children with its leukemia drug Gleevec, the regulator announced today. The drug, a form of the company's existing medication Glivec, may now be prescribed to children diagnosed with a type of lymphoblastic leukemia.

The affliction occurs when a genetic abnormality causes certain proteins stimulating bone marrow to produce an excessive amount of immature white blood cells. This is the most common type of cancer in children, striking nearly 3,000 every year. It worsens rapidly if left untreated.

Gleevec was first approved in 2001 to treat certain forms of the disease; approval has since been expanded to cover other types.

The article FDA Approves Novartis Leukemia Drug to Treat Youth originally appeared on Fool.com.

Fool contributor Eric Volkman and The Motley Fool has no position in Novartis. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.


Increase your money and finance knowledge from home

What is Short Selling?

Make a profit when stocks prices fall.

View Course »

Introduction to Value Investing

Are you the next Warren Buffett?

View Course »

Add a Comment

*0 / 3000 Character Maximum